NeuroVive publishes supplementary prospectus

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS. 

Lund, Sweden, 20 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has established a supplementary prospectus (“Tilläggsprospekt”) for the prospectus regarding the offer to subscribe for Units in NeuroVive, published on 9 April 2018. The supplementary prospectus has been prepared due to the press release concerning the Orphan Drug Designation granted by the FDA in the United States, published on 18 April 2018. The Supplementary prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) in accordance with the financial instruments trading act, today, on 20 April 2018.

The supplementary prospectus is available on the company's website, www.neurovive.com, on the Swedish Financial Supervisory Authority website, www.fi.se, on the Stockholm Corporate Finance AB website, www.stockholmcorp.se, and on the Hagberg & Aneborn Fondkommission AB website, www.hagberganeborn.se.

Because of the supplementary prospectus having been established and registered, investors who have made a notification or otherwise consented to the purchase or subscription of the securities covered by the prospectus have the opportunity to withdraw their notification or consent. Such revocation shall be made no later than 24 April 2018.

Advisers

NeuroVive has appointed Stockholm Corporate Finance AB as financial advisor, Advokatfirman Lindahl KB as legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing institution in connection with the Rights Issue.

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Swedish financial instruments trading act. The information was submitted for publication, through the agency of the contact person set out below, at 10:45 a.m. CEST on 20 April 2018.

For more information please contact:

Daniel Schale, Director of Communications

+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

info@neurovive.com, www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

About Stockholm Corporate Finance

Stockholm Corporate Finance is a Swedish, independent and privately owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 43 M&A advisors and investment banks in 45 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. www.stockholmcorp.se

IMPORTANT INFORMATION

In certain jurisdictions, the publication or distribution of this press release may be subject to restrictions according to law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and abide by such restrictions. This press release does not contain or constitute an invitation or an offer to acquire, subscribe for or otherwise trade in shares or other securities in NeuroVive.

This press release may not be announced, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other country where such action is wholly or partially subject to legal restrictions. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions. Failure to comply with this instruction may result in a violation of the United States Securities Act of 1933 (the “Securities Act”) or laws applicable in other jurisdictions.